The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction

Kong, Xiangqi1; He, Gang2; Quan, Xiaoqing1; Tan, Zhixiong1; Yan, Fengjuan1; Chen, Xiehui1,3

2024-03-22

10.1097/MD.0000000000037637

MEDICINE   影响因子和分区

0025-7974

1536-5964

This study aimed to investigate the impact of the latest guidelines on the real-world clinical practice of initial lipid-lowering therapy, especially on the use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in China. All adult patients diagnosed with acute myocardial infarction in our hospital between August 31, 2018, and August 31, 2020, were divided into the following 2 groups: those patients treated before the latest guideline release, and those patients treated after the release. A propensity score-matched method was used, and logistic regression was used to assess the association with intensive statin, ezetimibe and PCSK9 inhibitor usage together with treatment results between the 2 groups. A total of 325 patients were enrolled in this study, including 141 patients who were admitted before the release of the latest guideline and 184 patients who were admitted after the release. After a median follow-up time of 8.20 months, the mean low-density lipoprotein cholesterol was 1.87 +/- 0.59 mmol/L (1.87 +/- 0.55 in the before group vs 1.88 +/- 0.62 in the after group, P = .829). After propensity score matching, the initial usage of intensive statin therapy was decreased after guideline release without statistical significance (17.00% vs 28.00%, P = .090), whereas the usage of ezetimibe and PCSK9 inhibitors was increased (19.00% vs 8.00%, P = .039; and 10.00% vs 3.00%, P = .085, respectively). In logistic regression models, the release of the guideline was associated with a statistically significantly increased use of ezetimibe (odds ratio [OR]: 1.91; 95% confidence interval [CI]: 1.21, 3.02; P = .005), a marginally decreased use of intensive statins (OR: 0.68; 95% CI: 0.45, 1.03; P = .069) and a marginally increased use of PCSK9 inhibitors (OR: 1.31; 95% CI: 0.98, 1.76; P = .068). In this single-center, real-world data analysis, after the release of the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines, an increasing number of patients with a recent acute myocardial infarction were initially receiving ezetimibe and PCSK9 inhibitors.

ezetimibe lipid-lowering therapy PCSK9 inhibitors real-world study

SCI

英语

第一 ; 通讯

Shenzhen Longhua District Medical and Health Institutions District-level Scientific Research Project[2022035] ; Scientific Research Projects of Medical and Health Institutions of Longhua District, Shenzhen[2022035] ; Shenzhen Longhua District Foundation of Science and Technology[10162A20220810B2051AC]

General & Internal Medicine

Medicine, General & Internal

WOS:001196708800010

LIPPINCOTT WILLIAMS & WILKINS

CLINICAL MEDICINE

Web of Science

1.Southern Univ Sci & Technol, Shenzhen Longhua Dist Cent Hosp, Shenzhen Peoples Hosp, Affiliated Hosp 1, Shenzhen, Peoples R China
2.Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Affiliated Hosp 1, Dept Tradit Chinese Med, Shenzhen, Peoples R China
3.Shenzhen Longhua Dist Cent Hosp Shenzhen City, Shenzhen, Guangdong Provi, Peoples R China

Kong, Xiangqi,He, Gang,Quan, Xiaoqing,et al. The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction[J]. MEDICINE,2024,103(12).

Kong, Xiangqi,He, Gang,Quan, Xiaoqing,Tan, Zhixiong,Yan, Fengjuan,&Chen, Xiehui.(2024).The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction.MEDICINE,103(12).

Kong, Xiangqi,et al."The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction".MEDICINE 103.12(2024).